Envisia Therapeutics, Inc.

Company Summary

Envisia Therapeutics, formed by Liquidia Technologies, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® platform to develop therapies for a variety of ocular conditions, the most advanced of which is ENV515, for the treatment of glaucoma.

Transaction Overview

  • Envisia Therapeutics announced the completion of a $25 million in Series A financing

Significance of the Transaction

With ENV515, Envisia brings a potentially revolutionary approach to advancing glaucoma pharmacotherapy In addition to ENV515, Envisia is using its proprietary PRINT® (Particle Replication In Non-Wetting Templates) technology platform to create a pipeline of small and large molecule particle-based ocular therapeutics

Healthios Role

If you would like to learn more information about this transaction contact us below.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Private Placement
Envisia Therapeutics, Inc.
Has completed a $25 million Series A Financing in conjunction with the “spin-off” of certain assets from Liquidia Technologies
The undersigned acted as exclusive advisor to Liquidia
Read More